STERIS plc (STE) has seen a mix of performance levels, as suggested by its recent Q4 underperformance and Q3 2024 revenue beating earnings per share (EPS). Investment companies like
Harvey Investment Co., LLC and Fruth Investment Management have invested in and acquired large shares of STE respectively.
Annual FY25 revenue growth has been revised to 6% due to issues with healthcare capital delays. The company's stock is expected to perform well in the buzz of upcoming Q3 earnings, and has seen its holdings increase by entities such as
GHP Investment Advisors Inc. Despite ongoing margin pressures, revenue growth remains robust. The company's 42% return over five years indicates longer-term stability.
Forsta AP Fonden has boosted its stake in STE recently. The earnings surprise streak and international revenue of Steris are the key focal points. Entropy Technologies LP and the Czech National Bank have acquired shares too. Stephens has raised the price target for Steris to $250. Steris's Q3 revenues stood at $1.4 billion, beating estimates with an adjusted EPS of $2.32. While Steris outperformed Nasdaq, there have been calls for strategic alliances to support its stock.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Fri, 21 Feb 2025 14:20:23 GMT -
Rating 5
- Innovation -5
- Information 7
- Rumor -3
